161 related articles for article (PubMed ID: 18007155)
1. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).
Döhr O; Hofmeister R; Treher M; Schweinfurth H
Invest Radiol; 2007 Dec; 42(12):830-41. PubMed ID: 18007155
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
3. Toxicological safety evaluation of gadobutrol.
Wack C; Steger-Hartmann T; Mylecraine L; Hofmeister R
Invest Radiol; 2012 Nov; 47(11):611-23. PubMed ID: 23011188
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
5. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
Tsuda N; Okada M; Murakami T
Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
[TBL] [Abstract][Full Text] [Related]
6. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
7. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
8. Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography.
Steger-Hartmann T; Graham PB; Müller S; Schweinfurth H
Invest Radiol; 2006 May; 41(5):449-59. PubMed ID: 16625108
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
[TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
11. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
12. A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings.
Kitajima K; Yoshikawa T; Seo Y; Ohno Y; Yano Y; Miki A; Kanda T; Kanata N; Azuma T; Sugimura K
Magn Reson Imaging; 2011 May; 29(4):579-83. PubMed ID: 21216550
[TBL] [Abstract][Full Text] [Related]
13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
14. Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
Schuhmann-Giampieri G
Arzneimittelforschung; 1993 Sep; 43(9):1020-4. PubMed ID: 8240452
[TBL] [Abstract][Full Text] [Related]
15. Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors.
Tsuda N; Kato N; Murayama C; Narazaki M; Yokawa T
Invest Radiol; 2004 Feb; 39(2):80-8. PubMed ID: 14734922
[TBL] [Abstract][Full Text] [Related]
16. Effect of isoflurane anesthesia and hypothermia on the hepatic kinetics of Gd-EOB-DTPA: evaluation using MRI of conscious mice.
Kiryu S; Inoue Y; Watanabe M; Ohtomo K
J Magn Reson Imaging; 2011 Aug; 34(2):354-60. PubMed ID: 21692139
[TBL] [Abstract][Full Text] [Related]
17. Preclinical testing of iopromide. 2nd communication: toxicological evaluation.
Krause W; Schöbel C; Press WR
Arzneimittelforschung; 1994 Nov; 44(11):1275-9. PubMed ID: 7848345
[TBL] [Abstract][Full Text] [Related]
18. MR arthrography: pharmacology, efficacy and safety in clinical trials.
Schulte-Altedorneburg G; Gebhard M; Wohlgemuth WA; Fischer W; Zentner J; Wegener R; Balzer T; Bohndorf K
Skeletal Radiol; 2003 Jan; 32(1):1-12. PubMed ID: 12525938
[TBL] [Abstract][Full Text] [Related]
19. Investigation using an HER-2/neu transgenic mouse model of a newly developed MR contrast agent with the effect of an antitumor drug.
Sonoda A; Nitta N; Ohta S; Nitta-Seko A; Murata S; Jo J; Tabata Y; Takahashi M; Tani T; Murata K
J Magn Reson Imaging; 2009 Oct; 30(4):907-10. PubMed ID: 19787744
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials.
Tanimoto A; Kadoya M; Kawamura Y; Kuwatsuru R; Gokan T; Hirohashi S
J Magn Reson Imaging; 2006 Apr; 23(4):499-508. PubMed ID: 16534755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
